Cerebrolysin: A Porcine-Derived Neuropeptide Preparation for Stroke and Cognitive Recovery

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to Cerebrolysin. Cerebrolysin is not FDA-approved for human use in the United States. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Cerebrolysin occupies an unusual position in the global pharmacology landscape. It holds regulatory approval in more than 50 countries for conditions including acute ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease. Neurologists in Austria, Russia, China, and across Eastern Europe prescribe it routinely. And yet it has never been approved by the US Food and Drug Administration, and independent systematic reviewers have repeatedly concluded that the evidence base does not support confident claims of benefit.

This article explains what Cerebrolysin is, what the clinical trial record shows, where the manufacturer-sponsored literature and the Cochrane Collaboration diverge, and why that disagreement matters for anyone trying to understand the compound honestly.

Key Takeaways

• Regulatory Status: Not FDA-approved for any indication in the United States. Approved in 50+ countries (Austria, Russia, China, and others) for stroke, TBI, vascular dementia, and Alzheimer's disease. As of April 2026, no US regulatory pathway exists.
• Research Stage: Extensive international RCT data exists, including multiple Phase II/III trials and several meta-analyses. Independent Cochrane reviews have consistently rated the overall evidence certainty as low to very low, and the 2023 Cochrane update found no beneficial effect on all-cause death in acute ischemic stroke, alongside a statistically significant increase in non-fatal serious adverse events.
• Availability: Not legally marketed for human use in the United States. Superpower does not offer this substance. Gray-market importation carries significant legal and safety risk.
• What it is: A proprietary porcine brain-derived extract containing low-molecular-weight neuropeptides and free amino acids, manufactured by EVER Neuro Pharma (Austria).
• What the evidence actually shows: Positive results in industry-sponsored RCTs, particularly for stroke rehabilitation and TBI; no independent confirmation of benefit; Cochrane reviews across three decades find insufficient evidence for routine use.

What Cerebrolysin Is and Where It Comes From

Origin and composition

Cerebrolysin is not a single peptide. It is a proprietary extract derived from purified porcine (pig) brain tissue, manufactured exclusively by EVER Neuro Pharma, headquartered in Austria. The preparation consists of a heterogeneous mixture of low-molecular-weight neuropeptides and free amino acids derived from enzymatic breakdown of porcine brain proteins. A 2023 analytical study by Yang and colleagues, published in the Journal of Chromatography B, used NanoLC-MS mass spectrometry to characterize the active peptide constituents and identified a complex mixture of short-chain peptides rather than a single defined molecular entity. This heterogeneity is clinically relevant: Cerebrolysin has no single compound identifier and cannot be replicated by any other manufacturer. The preparation is administered by intravenous infusion, typically at doses of 10 to 30 mL per day over multi-week courses.

Proposed mechanisms

The core hypothesis behind Cerebrolysin is that its neuropeptide constituents mimic the effects of endogenous neurotrophic factors, specifically brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and glial cell line-derived neurotrophic factor (GDNF). A 2023 narrative review by Rejdak, Sienkiewicz-Jarosz, Bienkowski, and Alvarez, published in Medicinal Research Reviews, summarized proposed mechanisms including promotion of neurogenesis, synaptic plasticity, angiogenesis, anti-inflammatory signaling, and modulation of amyloid-beta and tau pathways relevant to Alzheimer's disease. Note that several authors of that review have declared ties to EVER Neuro Pharma. An independent 2024 in-vitro study published in Cureus found that Cerebrolysin upregulated BDNF expression in affected neural cells alongside citicoline, providing supplementary mechanistic support, though in-vitro findings cannot be extrapolated to clinical outcomes without human trial confirmation.

The biological plausibility of neurotrophic-factor mimicry is well-established in principle: BDNF and NGF are integral to neuronal survival, synaptic remodeling, and recovery after ischemic injury. Whether the low-molecular-weight peptides in Cerebrolysin reproduce these effects after intravenous infusion and blood-brain barrier passage remains a subject of ongoing inquiry.

The Clinical Trial Record: What Industry-Sponsored Data Shows

Acute ischemic stroke: the CASTA and CARS trials

The largest acute ischemic stroke trial is the CASTA study. Heiss, Brainin, Bornstein, and colleagues published the main results in Stroke in 2012, reporting a double-blind, placebo-controlled RCT of Cerebrolysin 30 mL intravenously once daily for 10 days in 1,070 Asian patients (529 Cerebrolysin vs. 541 placebo) with acute ischemic stroke, all of whom also received aspirin 100 mg daily. The primary endpoint — a combined global directional test of NIHSS, modified Rankin Scale, and Barthel Index at day 90 — was not significantly different from placebo in the overall trial population. A post-hoc subgroup of patients with more severe strokes (NIHSS at baseline of 12 or above) showed a nominally favorable mortality signal (10.5% vs. 20.2%). The trial was designed and sponsored by EVER Neuro Pharma, a point the investigators disclosed; the Hong and colleagues 2009 protocol paper in the International Journal of Stroke documented the pre-specified endpoints and dose.

The CARS program was designed to follow up on CASTA's null primary endpoint. Muresanu, Heiss, Hoemberg, and colleagues published CARS-I results in Stroke in 2016, reporting a randomized, placebo-controlled, double-blind multicenter trial of Cerebrolysin 30 mL intravenously once daily for 21 days plus standardized rehabilitation in 208 post-stroke patients (modified intention-to-treat on day 90: 205 patients, 104 Cerebrolysin vs. 101 placebo), initiated 24 to 72 hours after stroke onset. The primary outcome — Action Research Arm Test score at day 90 — favored Cerebrolysin with a Mann-Whitney estimator of 0.71 (95% CI 0.63 to 0.79; p < 0.0001), and the premature discontinuation rate was 3.8%. This is the most frequently cited positive Cerebrolysin stroke RCT; however, the sample was recruited in Eastern Europe, the trial was industry-sponsored, and the enrolled population was relatively small. A subsequent meta-analysis by Guekht and colleagues, published in Neurological Sciences in 2017, pooled CARS-I and CARS-II results and reported improved motor function recovery versus placebo; this meta-analysis included co-authors with EVER Pharma affiliations, and all pooled trials were industry-sponsored by the same manufacturer.

Post-stroke rehabilitation: Bornstein et al. meta-analysis

A 2018 meta-analysis by Bornstein and colleagues, published in Neurological Sciences, pooled nine randomized, double-blind, placebo-controlled trials including 1,879 patients in early post-stroke recovery and reported improved NIHSS changes at day 30 with Cerebrolysin (Mann-Whitney 0.60, p < 0.0001; number needed to treat 7.7, 95% CI 5.2 to 15.0), with modified Rankin Scale at day 90 favoring Cerebrolysin in the moderate-to-severe subgroup (Mann-Whitney 0.61, p = 0.0118). This is positioned as supporting the positive side of the evidence balance. However, a substantial proportion of the pooled trials overlap with the EVER Pharma-sponsored studies that independent reviewers have flagged for methodological concerns, including inadequate allocation concealment, high industry involvement, and short follow-up periods.

Traumatic brain injury: the CAPTAIN trials

For moderate-to-severe traumatic brain injury, Poon and colleagues published the CAPTAIN trial design paper in the Journal of Neurotrauma in 2015, outlining the methodology for an Asian-Pacific RCT series. The CAPTAIN I results, published in Neurological Sciences in 2020 by Poon, Matula, Vos, and colleagues, reported a double-blind, placebo-controlled RCT in 46 patients (22 Cerebrolysin vs. 24 placebo) with moderate-to-severe TBI, dosing Cerebrolysin 50 mL daily for 10 days followed by two 10 mL cycles of 10 days each; the primary multidimensional ensemble of 14 outcome scales at day 90 reached statistical significance per protocol (Mann-Whitney 0.69, 95% CI 0.53 to 0.85; p = 0.024) but narrowly missed in intention-to-treat (p < 0.1). The very small sample substantially limits the strength of this finding. A prospective meta-analysis of the CAPTAIN series published in 2021 by Vester and colleagues in Neurological Sciences reported favorable multidimensional outcomes; this analysis was industry-sponsored and represents the same manufacturer-adjacent evidence pattern seen across the stroke literature.

Vascular dementia and Alzheimer's disease

The dementia evidence base has a longer history. Ruether, Ritter, Apecechea, and colleagues published an early landmark placebo-controlled RCT in Journal of Neural Transmission Supplement in 2002, reporting sustained cognitive and global improvement on the ADAS-cog and CIBIC+ scales over six months in patients with moderately severe Alzheimer's disease. Plosker and Gillis reviewed the accumulated dementia evidence in Drugs & Aging in 2009, providing a comprehensive pharmacology, efficacy, and tolerability profile of Cerebrolysin in dementia available at that time. Plosker followed up with a 2010 companion review in CNS Drugs that summarized the dementia evidence as a shorter drug-profile reference. Alvarez, Cacabelos, Sampedro, and colleagues published a dose-ranging, randomized, double-blind, placebo-controlled trial in the European Journal of Neurology in 2011, analyzing 133 patients (ITT data set) with moderate to moderately severe AD (MMSE 14 to 20) drawn from a parent dose-finding study, randomized to Cerebrolysin 10, 30, or 60 mL diluted in 100 mL saline or placebo via IV infusion over 12 weeks (5 days/week for 4 weeks, then 2 days/week for 8 weeks), and reporting significant improvement in global clinical function on CIBIC+ across all three doses, with cognitive improvement on ADAS-cog+ most pronounced at the 10 mL dose; the study was industry-sponsored and the relatively small subgroup size limits the strength of the finding. A 2022 mechanistic RCT by Alvarez, Cacabelos, and colleagues in the Journal of Alzheimer's Disease analyzed plasma neuronal-derived extracellular vesicles and found that Cerebrolysin modulated amyloid-beta and tau biomarkers in patients also receiving donepezil, providing mechanism-level support at a biomarker level, though the sample was small and industry affiliation was declared.

The Cochrane Reviews: A Consistent Counter-Narrative

What independent systematic reviews have found

The Cochrane Collaboration has reviewed Cerebrolysin for acute ischemic stroke across three successive editions, and the conclusions have been consistent. Ziganshina and Abakumova published the original Cochrane review in 2010, establishing the methodological concerns that would carry through subsequent editions. An updated review by Ziganshina, Abakumova, and Hoyle in the Cochrane Database of Systematic Reviews in 2020 reached the same skeptical conclusion, reporting no benefit on all-cause death (RR 0.90, 95% CI 0.61 to 1.32; 6 trials, 1,517 participants) and a signal of increased non-fatal serious adverse events (RR 2.15, 95% CI 1.01 to 4.55). The most recent update, published by Ziganshina, Abakumova, Nurkhametova, and Ivanchenko in the Cochrane Database of Systematic Reviews in 2023, pooled seven RCTs with a total of 1,773 participants and found no evidence of beneficial effect on all-cause death (RR 0.96, 95% CI 0.65 to 1.41; 6 trials, 1,689 participants; moderate-certainty evidence). Critically, the same update found a statistically significant increase in non-fatal serious adverse events in the Cerebrolysin group (RR 2.39, 95% CI 1.10 to 5.23; 3 trials, 1,335 participants), with the signal more pronounced at the 30 mL for 10 days dose (RR 2.87, 95% CI 1.24 to 6.69). The authors rated the overall certainty of evidence for benefit as low to very low.

For vascular dementia, a Cochrane review by Chen, Yang, Guo, and Zhou, published in 2013, pooled six RCTs with 597 participants and found improvements in cognition and global clinical impression, but flagged short follow-up periods of six months or less, small sample sizes, and heterogeneous outcome reporting, concluding there was insufficient evidence to recommend Cerebrolysin as a routine treatment. An updated Cochrane review by Cui, Chen, Wu, and colleagues in 2019 confirmed modest short-term cognitive benefit in vascular dementia but maintained that the low-to-moderate evidence quality does not support recommending routine use.

Why the disagreement exists

The divergence between industry-sponsored meta-analyses and independent Cochrane reviews is not accidental. Cochrane reviewers have consistently identified concerns including non-independence of trial sponsors from outcome reporting, inadequate allocation concealment in several included trials, short follow-up windows, and the concentration of positive results in one manufacturer's research program. An independent systematic review and meta-analysis by Alsulaimani and Quinn, published in Cerebral Circulation - Cognitive and Behavioral in 2021, examined animal-derived nootropics including Cerebrolysin, Actovegin, and Cortexin in cognitive disorders and concluded that while these agents showed potential benefits and relative safety, the supporting evidence was weak and observed effects were probably less than would be considered clinically relevant. A secondary cost-effectiveness analysis of the CARS data by Strilciuc and colleagues, published in Healthcare (Basel) in 2023, reported a favorable incremental cost-effectiveness ratio for Cerebrolysin adjunct to rehabilitation; this analysis was industry-affiliated and does not resolve the primary evidence quality questions the Cochrane authors have raised.

This pattern does not mean Cerebrolysin is ineffective. It means the available evidence cannot confidently distinguish between a real treatment effect and the combination of methodological limitations and publication bias from a single interested sponsor.

Regulatory and Legal Status

FDA classification

As of April 2026, Cerebrolysin is not approved by the FDA for any indication. It has not been reviewed under a New Drug Application and has no FDA-cleared indication in the United States. Because Cerebrolysin is a proprietary porcine brain extract with no single defined active pharmaceutical ingredient and no US NDA history, it does not fit the standard compounding framework applicable to identified drug substances. It is not available through any licensed US pharmaceutical channel.

International approval context

Cerebrolysin holds regulatory approval in Austria, Russia, China, South Korea, and more than 50 countries globally for indications including acute ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer's disease. The European Medicines Agency has not issued an EU-wide centralized approval; approvals are held at the national level in individual European countries. The extensive international approval record reflects regulatory decisions made under different evidentiary thresholds and at different points in time than current US or EU standards would require. International approval is not equivalent to FDA approval and does not indicate that the FDA has evaluated or would approve the compound.

What this means practically

Products labeled as Cerebrolysin sold through online vendors or gray-market importers are not regulated by the FDA. There is no legal pathway to obtain pharmaceutical-grade Cerebrolysin for human use in the United States outside of an FDA-approved clinical trial. Importation for personal use carries legal and safety risk. Dosing, sterility, and authenticity cannot be verified for unregulated sources, and the IV-infusion delivery route carries additional safety considerations that require clinical supervision.

Safety: What Is and Is Not Known

Clinical safety data from trials

Cerebrolysin has a larger human safety dataset than most research peptides, given its international clinical use. Within the industry-sponsored RCTs, adverse events were generally reported as comparable between Cerebrolysin and placebo arms. The notable exception is the 2023 Cochrane update, which found a statistically significant increase in non-fatal serious adverse events (RR 2.39, 95% CI 1.10 to 5.23; 3 trials, 1,335 participants) across pooled trials. The Cochrane reviewers rated this finding as low-certainty evidence, meaning the true effect may differ substantially from the point estimate, but the signal is present and cannot be dismissed. Common adverse effects reported in clinical trials include headache, dizziness, agitation, and injection-site reactions. The overall tolerability profile in controlled settings appears manageable, but long-term safety data independent of manufacturer-sponsored studies is limited.

Risks from unregulated sources

Outside of pharmaceutical-grade, clinically supervised settings, Cerebrolysin carries the risks inherent to any IV-administered compound from unverified sources: contamination, sterility failure, incorrect concentration, and absence of verified porcine sourcing. Because the compound's efficacy and safety profile are tied to a specific, proprietary extraction process, products labeled as Cerebrolysin from non-EVER Neuro Pharma sources cannot be assumed to replicate the preparation studied in clinical trials.

Who Should Not Use Cerebrolysin

Based on Cerebrolysin's proposed mechanisms and the available trial data, the following groups face elevated theoretical or documented risk:

• Individuals with known hypersensitivity to porcine-derived products — the preparation's biological origin means anaphylactic risk exists for those with pork protein sensitivities
• Individuals with active seizure disorders — seizure has been reported as a serious adverse event in trial data; neurostimulatory mechanisms warrant caution
• Individuals with severe renal failure — renal impairment may affect excretion of the preparation's low-molecular-weight constituents; clinical trials have excluded this population
• Pregnant or breastfeeding individuals — no safety data exists in these populations; no use should be considered outside a supervised clinical setting
• Individuals seeking unsupervised, non-clinical use — IV administration outside a medical setting carries independent risk of infection, air embolism, and dosing error regardless of the compound involved
• Anyone sourcing the compound outside the licensed pharmaceutical supply chain — purity, sterility, and authenticity cannot be guaranteed

Which Biomarkers Are Relevant if You Are Exploring This Science?

Cerebrolysin's proposed mechanisms intersect with several measurable biological pathways. If the underlying biology interests you — or if you are navigating cognitive concerns, vascular risk, or recovery from neurological events — the following markers provide objective baseline context that supports any clinical conversation.

• High-sensitivity CRP (hs-CRP): Measures systemic inflammatory activity. Neuroinflammation is one proposed target of Cerebrolysin's neurotrophic-factor mimicry; baseline hs-CRP helps establish whether systemic inflammation is a contributing factor to cognitive or neurological symptoms.
• Homocysteine: Elevated homocysteine is independently associated with vascular endothelial injury, white matter disease, and accelerated cognitive decline. It is a modifiable vascular risk factor relevant to anyone concerned about brain vascular health or stroke risk.
• Glucose: Glucose metabolism is central to neuronal energy supply. Hyperglycemia worsens outcomes in acute ischemic stroke, and insulin resistance is associated with increased risk of vascular dementia and Alzheimer's disease. Baseline glucose and HbA1c characterize this important metabolic dimension.
• IGF-1: Insulin-like growth factor 1 shares functional overlap with the neurotrophic pathways Cerebrolysin is proposed to activate. IGF-1 supports neuronal survival and synaptic plasticity; its levels decline with age and in conditions associated with cognitive decline, making it a meaningful baseline marker for anyone evaluating their neurotrophic biology.
• Fasting lipids (total cholesterol, LDL, HDL, triglycerides, ApoB): Vascular risk factors including dyslipidemia drive both ischemic stroke risk and the cerebrovascular pathology underlying vascular dementia. Understanding your lipid profile is foundational to any serious assessment of long-term cognitive health.
• Complete blood count (CBC): Hemoglobin, hematocrit, and platelet count are relevant to stroke risk, recovery, and the hematologic safety monitoring recommended when considering any neurovascular intervention.
• Comprehensive metabolic panel: Renal and hepatic function markers establish the safety baseline relevant to any IV-administered investigational compound and inform the clinical picture for patients with vascular or metabolic risk factors.

When to Take This Seriously

If you are researching Cerebrolysin because you or someone close to you has experienced a stroke, TBI, or is living with cognitive decline, those are conditions with established clinical pathways. Neurologists, physiatrists, and primary care physicians with expertise in vascular neurology can evaluate the full range of evidence-supported rehabilitation and pharmacological approaches. Cerebrolysin is not available in the United States through legal channels, and the independent evidence base does not currently support recommending it over established approaches. Understanding your markers of cognitive and metabolic health through bloodwork gives you and your provider objective data to work with, independent of what compounds are or are not accessible.

That commitment to data before decisions is what drives Superpower's approach to preventive health: the belief that understanding your biology is the foundation for every health decision, whether you are navigating an established therapeutic choice or evaluating compounds with contested evidence bases.

IMPORTANT SAFETY INFORMATION

Cerebrolysin is NOT FDA-approved for any indication in the United States. No US pharmaceutical channel, prescription pathway, or compounding authorization exists for this compound. Superpower Health does not prescribe, sell, compound, or facilitate access to Cerebrolysin. This educational content is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendation.

Warnings: The 2023 Cochrane systematic review found a statistically significant increase in non-fatal serious adverse events in the Cerebrolysin group compared to placebo (RR 2.39, 95% CI 1.10–5.23; 3 trials, 1,335 participants) across pooled acute ischemic stroke trials; seizure has been reported as a serious adverse event in clinical trial data; IV administration outside a supervised clinical setting carries independent risk of infection, air embolism, and dosing error.

Contraindications (based on clinical trial exclusion criteria and compound characteristics): Known hypersensitivity to porcine-derived products; severe renal failure; active seizure disorder; pregnancy and breastfeeding (no safety data available).

Common adverse effects reported in clinical trials: headache, dizziness, agitation, injection-site reactions.

Importation and gray-market sourcing: Products labeled as Cerebrolysin from non-pharmaceutical sources are unregulated. Sterility, purity, concentration, and authenticity cannot be verified. The proprietary manufacturing process of the approved product cannot be replicated outside the licensed manufacturer. As of April 2026, importation for personal use in the United States is unauthorized and carries legal and safety risk.

Long-term data: Independent long-term safety data for Cerebrolysin outside industry-sponsored trials is limited. The overall evidence certainty for benefit has been rated low to very low by Cochrane reviewers across three systematic review editions (2010, 2020, 2023).

Additional Questions

What did the Cochrane review find about Cerebrolysin?

The 2023 Cochrane systematic review by Ziganshina, Abakumova, Nurkhametova, and Ivanchenko pooled seven RCTs including 1,773 participants with acute ischemic stroke. It found no evidence of beneficial effect on all-cause death (RR 0.96, 95% CI 0.65 to 1.41) and a statistically significant increase in non-fatal serious adverse events (RR 2.39, 95% CI 1.10 to 5.23; 3 trials, 1,335 participants). The authors rated the overall certainty of evidence as low to very low. This represents the third successive Cochrane edition reaching the same skeptical conclusion, following earlier versions published in 2010 and 2020.

Why is Cerebrolysin approved in so many countries if the evidence is uncertain?

International regulatory approvals were granted at different points in time and under different evidentiary standards than current FDA requirements. Many approvals predate the 2023 Cochrane findings. Regulatory bodies in different jurisdictions weigh the available evidence differently, particularly for conditions with limited therapeutic options. International approval does not constitute FDA endorsement and does not resolve the methodological concerns independent reviewers have raised.

What biomarkers are relevant to stroke and cognitive health?

For vascular risk relevant to stroke, key markers include fasting lipids (LDL, ApoB, HDL), homocysteine, glucose, and HbA1c. For inflammation, hs-CRP provides a systemic measure. IGF-1 is relevant to neurotrophic biology. A comprehensive metabolic panel covers kidney and liver function. These markers do not assess Cerebrolysin's effects directly, but they characterize the vascular and metabolic biology that underlies the conditions Cerebrolysin is studied for.